Answers are grounded in this paper and cite their sources.
The high costs of cancer care can cause significant harm to patients and society. Prostate cancer, the leading nonskin malignancy in men, is responsible for the second-highest out-of-pocket (OOP) payments among all malignancies. Multiple first-line treatment options exist for metastatic castration-resistant prostate cancer (mCRPC); although their costs vary substantially, comparative effectiveness data are limited. There is little evidence of how gross payments made by insurers and OOP payments made by patients differ by treatment and health plan type and how these payment differences relate to utilization.
No takes yet. Share an insight, caveat, or question.
Kaye et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: